CBD Regulation UK - MHRA, FSA, Legal Guide

CBD Regulation in the UK: A Comprehensive Guide

The cannabidiol (CBD) market in the United Kingdom has experienced substantial growth over recent years, but regulatory compliance remains complex and multifaceted. This guide outlines the key regulatory frameworks governing CBD products In 2026, including Food Standards Agency requirements, Medicines and Healthcare Products Regulatory Agency rules, and specific restrictions on tetrahydrocannabinol content and consumer labelling.

Overview of the UK CBD Regulatory Landscape
in 2026, CBD products in the UK fall under multiple regulatory jurisdictions depending on their intended use and composition. The primary regulators include the Food Standards Agency (FSA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and Trading Standards authorities. Understanding which authority governs your product is crucial for compliance and market authorisation.

CBD is classified as a Novel Food in the UK, meaning it was not significantly consumed before May 1997. This classification requires specific authorisation procedures and approval before products can be legally sold to consumers.

FSA Novel Food Authorisation

The FSA’s Novel Foods Regulation represents the most significant regulatory pathway for CBD products marketed as foods or food supplements in 2024.

Novel Food Application Requirements

CBD products must undergo FSA authorisation before being placed on the market as foods
Applications require comprehensive safety data, toxicology studies, and proposed usage levels
The authorisation process involves scientific evaluation and can take 12-18 months or longer
Applicants must demonstrate the product’s safety for the intended population

Current Status (2024): Several CBD products have received provisional listing from the FSA, but full authorisation for CBD as a Novel Food remains limited. Products without authorisation cannot legally be sold as foods or food supplements in the UK.

Businesses seeking FSA approval must submit detailed applications including:

Chemical composition and manufacturing specifications
Nutritional and metabolic studies
Toxicological data and safety assessments
Proposed labelling and usage instructions
Post-market monitoring plans

MHRA Medicinal Claims and Authorisation

The MHRA strictly regulates any CBD product making therapeutic or medicinal claims. This is a critical distinction affecting how products are marketed and sold.

Prohibited Medicinal Claims

CBD products cannot make any of the following claims without MHRA authorisation as a medicinal product:

Treatment or cure of medical conditions (anxiety, epilepsy, pain, etc.)
Reduction of disease symptoms or signs
Prevention or diagnosis of diseases
Restoration, correction, or modification of bodily functions
Any other claims that imply therapeutic benefit

Products making medicinal claims require licensing as medicines, which demands clinical trial data, quality assurance documentation, and ongoing pharmacovigilance. The MHRA’s approach is particularly stringent regarding CBD, reflecting current scientific uncertainty around efficacy.

Permitted claims for CBD products marketed as foods or supplements are limited to:

General nutrition information
Authorised health claims (though few currently exist for CBD)
Structure-function claims that don’t imply disease treatment

THC Limit Requirements

Tetrahydrocannabinol (THC) content is strictly controlled under UK law, with negligible tolerance for this psychoactive compound.

Legal THC Limit: CBD products must contain no more than 0.2% THC by weight to comply with UK legislation. Any product exceeding this threshold is classified as a controlled drug and cannot be legally supplied to consumers.

This requirement means:

Full-spectrum CBD products must be tested and verified to contain less than 0.2% THC
Broad-spectrum and isolate products should naturally comply but require testing verification
Batch testing from accredited laboratories is essential and strongly recommended
Products must maintain THC compliance from manufacture through distribution

Manufacturers must maintain detailed testing records and supply certificates of analysis with each batch to demonstrate compliance with THC limits.

Age Restrictions and Consumer Access

Whilst no statutory age restriction exists for purchasing CBD products In 2026, important considerations apply to responsible supply and marketing:

Many retailers voluntarily implement 18+ age restrictions for CBD products
Marketing must not target minors or suggest use by those under 18
Products must not be sold in settings predominantly accessed by children
Online retailers should implement age verification systems for CBD purchases
Packaging and advertising should not appeal to minors

Trading Standards and local authorities may take action against retailers who fail to implement responsible age controls, particularly for high-strength products or products marketed with appeal to younger consumers.

Labelling and Information Requirements

Comprehensive labelling is mandatory for all CBD products placed on the UK market in 2024.

Required Label Information

CBD content: Clear indication of milligrams per serving and per container
Ingredients: Complete list of all ingredients in descending order by weight
Allergen information: Any known allergens clearly highlighted
Dosage instructions: Clear guidance on recommended usage
Safety warnings: Warnings for pregnancy, breastfeeding, and medication interactions
Storage instructions: Proper storage conditions and shelf life
Manufacturer details: Name and address of responsible person
Batch number and date: Traceability information
THC content: Clear statement that THC content is within legal limits (less than 0.2%)

Labels must not include:

Medicinal or therapeutic claims without MHRA authorisation
Unsubstantiated health benefits or efficacy claims
Images or language targeting minors
References suggesting CBD cures disease or replaces medical treatment

Testing and Quality Assurance

Third-party laboratory testing is essential for demonstrating compliance and building consumer confidence:

CBD potency and purity analysis must be conducted by accredited laboratories
Microbial contamination testing is strongly recommended and expected for edible products
Heavy metal analysis demonstrates commitment to safety standards
Residual solvent testing verifies manufacturing safety
Certificates of Analysis should be readily available to consumers

Compliance and Penalties

Non-compliance with CBD regulations can result in serious consequences, including product seizure, business prosecution, and significant financial penalties. Businesses should maintain comprehensive documentation of product sourcing, testing, and marketing compliance.

CBD Regulation UK – MHRA, FSA, Legal Guide